PharmaTimesOriginal article
Erasca secures FDA fast track for eras‑0015 in pancreatic cancer
Regulatoryeras-0015Positive
AI Analysis
Summary
Erasca has received FDA fast track designation for eras-0015, a pan-RAS molecular glue inhibitor being developed for pancreatic cancer treatment, supporting accelerated development of the compound.
Outcome Details
FDA fast track designation granted
Importance:6/10
Sentiment:
0.70
FDA Fast Trackpan-RASmolecular gluepancreatic canceroncology
Read the original article
Published by PharmaTimes on August 27, 2026 9:51 AM